EVALUATING THE IMPACT OF LYMPOVASCULAR INVASION ON SURVIVAL OF SURGICALLY TREATED PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA: A NATIONWIDE ANALYSIS
Recommended Citation
Corsi N, Cirulli GO, Chiarelli G, Finati M, Davis M, Rogers C, Abdollah F, Rakic I, Morrison C, Stephens A, Sood A, Lughezzani G, Salonia A, Buffi N, Briganti A, Montorsi F, Carrieri G. EVALUATING THE IMPACT OF LYMPOVASCULAR INVASION ON SURVIVAL OF SURGICALLY TREATED PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA: A NATIONWIDE ANALYSIS. Urol Oncol 2024; 42:S106-S106.
Document Type
Conference Proceeding
Publication Date
3-1-2024
Publication Title
Urol Oncol
Abstract
Introduction: Lymphovascular invasion (LVI) is recognized as an adverse prognostic factor in many cancers. However, its utility in upper tract urothelial carcinoma (UTUC) has not been well-defined. Our aim was to assess the prognostic ability of LVI in UTUC as a predictor of overall survival (OS) using a large North American cohort. Methods: Our cohort included 5,940 cM0 UTUC patients who underwent a radical nephroureterectomy (RNU), between 2004 and 2016, within the National Cancer Database (NCDB). The main variable of interest was LVI status, and its interaction with pathological nodal (pN) status. Kaplan-Meier curves were used to depict the OS also stratifying patients on LVI status. Cox regression analysis tested the impact of LVI status on OS after accounting for the available covariates. Results: Median (IQR) for age at diagnosis was 71 (63 – 78) and most patients had pT1 stage disease (48.6%). Nodal status was pN0, pN1 and pNx in 45.8%, 6.3% and 47.9%, respectively. Overall, 22.1% had LVI. The median (IQR) follow-up time was 32.6 (16 – 53.3) months. At 5-years postoperative follow-up, the estimated OS rate was 28% in patients with LVI vs. 66% in those without LVI (p<0.001). When patients were stratified based on nodal status those rates were 32% vs 68% in pN0 patients (p<0.001; Figure 1), 23% vs 30% in pN1 patients (p = 0.8), and 28% vs 65% in pNx patients (p<0.001). On multivariable analysis, the presence of LVI was associated with less favorable OS (HR 1.79, 95% CI: 1.60-1.99, p<0.001). Conclusions: Our study assessed the impact of LVI on OS in UTUC patients in a large North American nationwide cohort. Our series, as the largest to-date, indicate that LVI is associated with less favorable survival outcomes in UTUC patients after RNU, and this variable could be used as a risk-stratification tool for future adjuvant therapy trials.
Volume
42
First Page
S106
Last Page
S106
